z-logo
open-access-imgOpen Access
Effect Observation of Clinical Treatment with Oxaliplatin and Tiggio for Biliary Tract Tumors on Advanced Stage
Author(s) -
Wei Zheng,
Haibin Wang,
Jiao Zhou
Publication year - 2021
Publication title -
journal of clinical and nursing research
Language(s) - English
Resource type - Journals
eISSN - 2208-3693
pISSN - 2208-3685
DOI - 10.26689/jcnr.v5i3.2001
Subject(s) - oxaliplatin , medicine , gemcitabine , incidence (geometry) , adverse effect , gastroenterology , colorectal cancer , surgery , cancer , physics , optics
Objective: To investigate the effect of oxaliplatin combined with tiggio in the treatment of advanced biliary tract tumors. Methods: The research period was from November 2019 to November 2020. 80 patients with advanced biliary tumor disease were enrolled. They were divided into groups according to the order of admission, with 40 cases in each group. The control group received oxaliplatin combined with gemcitabine, and the experimental group received oxaliplatin combined with tiggio. Incidence of adverse reactions, time to disease progression, survival time and clinical efficacy were checked and assessed. Results: Compared with the incidence of adverse reaction of the experimental group, which was 5.00% (2/40), the incidence of adverse reaction of the control group was 25.00% (10/40). The chi-square value = 6.2745, p-value = 0.0122. The time to progression and survival time of patients in the experimental group were shorter than those of the control group, with significant differences between the groups (p<0.05); the clinical efficacy of the experimental group and the control group were 97.50% (39/40) and 77.50% (31/ 40) respectively, the comparative chi-square value = 7.3143, p-value = 0.0068. Conclusion: The combined treatment of oxaliplatin and Tiggio in the treatment of advanced biliary tract tumors has higher safety and reduces the incidence of adverse reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here